breast cancer

[Science Signaling] Researchers identified delayed down-regulated genes (DDGs) in mammary cells after prolonged treatment with epidermal growth factor (EGF). The expression of these DDGs was low in mammary tumors and correlated with prognosis.

[Signal Transduction and Targeted Therapy] Investigators found that the nonclassical histocompatibility antigen HLA-G desensitized breast cancer cells to trastuzumab by binding to the natural killer cell receptor KIR2DL4.

[Cellular and Molecular Life Sciences] The authors describe the cellular and molecular features of the luminal cell lineage expressing estrogen receptor-α (ERα) and provide an overview of the transgenic mouse models impacting ERα signaling, highlighting the pivotal role of ERα in mammary gland morphogenesis and function and its implication in the tumorigenic processes.

[International Immunopharmacology] Personalized immunotherapy has recently been proposed as a potential complementary medicine with immunotherapy and chemotherapy for overcoming breast cancer (BC). Scientists discuss the brief association of these methods and future directions in BC immunotherapy.

[Susan G. Komen®] Susan G. Komen® announced the addition of six esteemed breast cancer researchers and three new patient advocates to important advisory roles. These women and men join a group of breast cancer researchers, clinicians and advocates who help guide the organization’s $1.1 billion research program.

[ImmunityBio, Inc.] ImmunityBio, Inc. announced it has received FDA authorization to conduct a Phase Ib/II open-label study to evaluate the safety and preliminary efficacy of its superagonist Anktiva and PD-L1 targeted high-affinity natural killer (t-haNK) cells in combination with standard chemo and Trodelvy, in subjects with advanced TNBC.